Kymera Therapeutics, Inc. KYMR
134.84 USD -1.80 (-1.32%)
At closeNov 11, 2026, 4:00 PM EST
134.84 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
134.57 Day range 138.01
61.50 52-week range 142.92
- YTD
- +73.29%
- 1 year
- +112.78%
News
benzinga.com Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $170 Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $139 to $170.- benzinga.com Truist Securities Reiterates Buy on Kymera Therapeutics, Raises Price Target to $150 Truist Securities analyst Srikripa Devarakonda reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $136 to $150.
benzinga.com RBC Capital Maintains Sector Perform on Kymera Therapeutics, Raises Price Target to $116 RBC Capital analyst Brian Abrahams maintains Kymera Therapeutics (NASDAQ:KYMR) with a Sector Perform and raises the price target from $112 to $116.
benzinga.com BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $139 BTIG analyst Jeet Mukherjee maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $134 to $139.- benzinga.com Kymera Therapeutics Q3 EPS $(1.32) Misses $(1.27) Estimate Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.27) by 3.94 percent. This is a 40.43 percent decrease over losses…
- benzinga.com Morgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146 Morgan Stanley analyst James Quigley maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $135 to $146.